News Sentiment

KYTX sentiment intelligence

Kyverna Therapeutics, Inc. Common Stock news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 59 Balanced news tone 73 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 8.49 Week of 10 Jul 2026
Weighted tone 59/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

80/100 classification confidence.

Company focus 66

directly relevant articles

Source quality 6

high-authority source matches

Trend context Trend inactive

-4.6% over one week, +5.3% over four weeks, trend inactive, and near fair-value range.

Latest direct headline Positive

Dow, Nasdaq, S&P 500 Futures Edge Higher After Trump Extends Iran Ceasefire: POET, NVTS, KYTX, TSLA Stocks Garner Focus Today

Market Reaction

Price moving ahead of tone

69/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 80/100 classification
One-week reaction -4.6% Price reacting lower
Trend fit Trend inactive 5.3% over four weeks
Fair value 4.7% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 26
Neutral 43
Negative 4

Relevance

Why the article matched

Direct first
Direct company coverage 66
Industry context 7
Sector context 0

Sources

Coverage mix

Publishers
Market source 9
TradingView 7
Stock Titan 4
GlobeNewswire 4
TradingKey 4
Seeking Alpha 3
Moomoo 3
Stocktwits 2

Event Lens

What the news is about

Classified themes
Market update 41
Earnings 21
Analyst action 7
Regulatory and legal 2
Balance sheet 1
Guidance 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 73
Market source Direct company coverage

Kyverna Therapeutics Sinks 13%: Here’s Why

Kyverna Therapeutics (NASDAQ:KYTX) shares dropped almost 13% after JPMorgan cut its price target to $29, despite the company reporting better-than-expected Q1 2026 results and initiating a rolling BLA submission for its lead asset, miv-cel. The fresh analyst note is cited as the

Tone
Negative 18/100
Event
Analyst action
Published
10 Jul 2026 19:59
Source
Market source
MarketBeat Direct company coverage

Kyverna Therapeutics (NASDAQ:KYTX) Shares Down 11.1% - Time to Sell?

Kyverna Therapeutics (NASDAQ:KYTX) stock dropped 11.1% in mid-day trading on Friday, with shares hitting $8.90. This decline occurred despite the clinical-stage biotech reporting a smaller-than-expected quarterly loss of ($0.66) per share, beating estimates. Analyst opinions are

Tone
Negative 40/100
Event
Analyst action
Published
10 Jul 2026 16:40
Source
MarketBeat
TradingView Direct company coverage

Price to sales forward of Kyverna Therapeutics, Inc. – NASDAQ:KYTX

This article provides the "Price to sales forward" metric for Kyverna Therapeutics, Inc. (NASDAQ: KYTX) as listed on TradingView. It indicates that the period value and changes for this financial metric are made available by humans. The content is primarily a data point for inves

Tone
Neutral 50/100
Event
Market update
Published
10 Jul 2026 05:41
Source
TradingView
TipRanks Direct company coverage

Kyverna Therapeutics Amends Term Loan, Extends Capital Access

Kyverna Therapeutics recently amended its $150 million term loan facility with Oxford Finance, extending access to $15 million of Term A loans until year-end 2026. This amendment involves upfront and potential non-utilization fees and introduces contingent changes to Term B and T

Tone
Neutral 50/100
Event
Market update
Published
10 Jul 2026 05:41
Source
TipRanks
Quartr Direct company coverage

Kyverna Therapeutics (KYTX) Jefferies London Healthcare Conference 2025 Summary

Kyverna Therapeutics (KYTX) presented at the Jefferies London Healthcare Conference 2025, highlighting their progress in CAR T therapies for autoimmune diseases. Their lead candidate, KYV-101, has shown strong efficacy and a favorable safety profile in over 100 patients across va

Tone
Positive 77/100
Event
Market update
Published
09 Jul 2026 17:40
Source
Quartr
Stock Titan Direct company coverage

Kyverna Therapeutics (KYTX) extends access to $150M term loan tranches

Kyverna Therapeutics has amended its $150 million non-dilutive term loan facility with Oxford Finance, extending access to $15 million of Term A Loans until December 31, 2026, for an upfront fee of $187,500. This amendment also restructures the availability of subsequent tranches

Tone
Neutral 50/100
Event
Market update
Published
09 Jul 2026 10:10
Source
Stock Titan
MarketBeat Direct company coverage

Kyverna Therapeutics, Inc. $KYTX Shares Bought by AIGH Capital Management LLC

AIGH Capital Management LLC increased its stake in Kyverna Therapeutics (NASDAQ:KYTX) by 33.3% in the first quarter, purchasing an additional 500,000 shares to bring their total holding to 2 million shares, valued at $17.26 million. This makes Kyverna Therapeutics the 10th larges

Tone
Positive 63/100
Event
Earnings
Published
09 Jul 2026 08:10
Source
MarketBeat
Seeking Alpha Direct company coverage

Kyverna Therapeutics: The Autoimmune CAR T Beachhead Is Bigger Than SPS (KYTX)

Kyverna Therapeutics is positioned to be a pioneer in the autoimmune CAR T space, with miv-cel as a potential first-in-class therapy for severe B-cell-driven autoimmune diseases. The company has regulatory alignment for a rolling BLA submission for SPS, targeting FDA approval by

Tone
Positive 77/100
Event
Regulatory and legal
Published
06 Jul 2026 11:41
Source
Seeking Alpha
Finviz Direct company coverage

KYTX - Kyverna Therapeutics Inc Dividends

This article provides comprehensive financial data for Kyverna Therapeutics Inc (KYTX), including its current stock price, market capitalization, income, sales, and various financial ratios. It highlights key performance metrics, insider and institutional ownership, and analyst r

Tone
Neutral 50/100
Event
Analyst action
Published
01 Jul 2026 10:39
Source
Finviz
marketscreener.com Direct company coverage

Kyverna Therapeutics, Inc.(NasdaqGS: KYTX) added to Russell 2000 Index

Kyverna Therapeutics, Inc. (NasdaqGS: KYTX) has been added to the Russell 2000 Index, as well as several other Russell benchmarks including the Russell 2500 Growth, Russell 2000 Growth, and Russell 3000 Index. This inclusion marks a significant milestone for the clinical-stage bi

Tone
Positive 75/100
Event
Market update
Published
30 Jun 2026 02:09
Source
marketscreener.com
www.marketscreener.com Direct company coverage

Kyverna Therapeutics, Inc.(NasdaqGS:KYTX) added to Russell Microcap Growth Benchmark Index

Kyverna Therapeutics, Inc. (NasdaqGS:KYTX) has been added to the Russell Microcap Growth Benchmark Index. This inclusion follows previous announcements of its addition to the Russell 2000 Growth and Russell 3000E Growth Benchmark Indices. Kyverna Therapeutics is a clinical-stage

Tone
Positive 66/100
Event
Market update
Published
29 Jun 2026 12:43
Source
www.marketscreener.com
TradingView Direct company coverage

Kyverna Therapeutics, Inc. Actuals & Estimates (NASDAQ:KYTX)

This article provides an overview of Kyverna Therapeutics, Inc. (NASDAQ: KYTX) stock performance, financial data, and analyst estimates. It highlights the current stock price, market capitalization, historical highs and lows, and future price forecasts from analysts, along with d

Tone
Positive 63/100
Event
Analyst action
Published
26 Jun 2026 12:39
Source
TradingView
TradingView Direct company coverage

KYTX Forecast — Price Target — Prediction for 2027

This article provides a forecast for Kyverna Therapeutics, Inc. (KYTX) stock, including price targets from analysts ranging from $25.00 to $33.00. It covers the stock's recent performance, volatility, market capitalization, and upcoming earnings report. The piece also includes fr

Tone
Positive 64/100
Event
Earnings
Published
25 Jun 2026 18:10
Source
TradingView
Moomoo Direct company coverage

Press Release: Kyverna Therapeutics Appoints Ritesh Srivastava as Chief Legal and Compliance Officer, Adding Leadership Strength to Support Commercial-Stage Transition

Kyverna Therapeutics has appointed Ritesh Srivastava as its Chief Legal and Compliance Officer, bringing over two decades of legal and compliance experience in the healthcare sector. This strategic hire aims to strengthen Kyverna's leadership team as it prepares for a potential c

Tone
Neutral 50/100
Event
Market update
Published
25 Jun 2026 18:10
Source
Moomoo
Market source Direct company coverage

Kyverna Therapeutics Appoints Ritesh Srivastava as Chief Legal and Compliance Officer, Adding Leadership Strength to Support Commercial-Stage Transition

Kyverna Therapeutics has appointed Ritesh Srivastava as Chief Legal and Compliance Officer, effective June 22, 2026, to bolster its leadership as it transitions to a commercial-stage organization. Srivastava brings extensive experience in legal, corporate strategy, compliance, an

Tone
Positive 72/100
Event
Market update
Published
22 Jun 2026 16:41
Source
Market source
GlobeNewswire Direct company coverage

Kyverna Therapeutics Appoints Ritesh Srivastava as Chief

Kyverna Therapeutics announced the appointment of Ritesh Srivastava as Chief Legal and Compliance Officer, effective June 22, 2026. Srivastava brings extensive experience in legal, corporate strategy, compliance, and risk management, which will be crucial as Kyverna advances its

Tone
Positive 71/100
Event
Market update
Published
22 Jun 2026 11:40
Source
GlobeNewswire
Moomoo Direct company coverage

Press Release: Kyverna Therapeutics Names Greg Martini as Chief Financial Officer

Kyverna Therapeutics has appointed Greg Martini as its new Chief Financial Officer. Martini brings over two decades of financial leadership experience in the biotechnology sector, including his previous role at Tempest Therapeutics. His appointment is expected to strengthen Kyver

Tone
Positive 72/100
Event
Market update
Published
20 Jun 2026 22:10
Source
Moomoo
TradingKey Direct company coverage

Kyverna Therapeutics Inc (KYTX) Institutional Confidence

This article provides details on the institutional confidence in Kyverna Therapeutics Inc (KYTX), listing key institutional shareholders and their shareholdings. It highlights the changes in holdings for top firms like VV Manager LLC, Westlake Village BioPartners, and GordonMD Gl

Tone
Positive 70/100
Event
Market update
Published
18 Jun 2026 10:09
Source
TradingKey
TradingKey Direct company coverage

Kyverna Therapeutics Inc (KYTX) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Kyverna Therapeutics Inc (KYTX), detailing future EPS and revenue growth estimates. It highlights that analysts have a "Buy" rating for KYTX, with a target price indicating a significant upside. The report also includes past EPS perf

Tone
Positive 71/100
Event
Earnings
Published
18 Jun 2026 10:09
Source
TradingKey
TradingKey Direct company coverage

Kyverna Therapeutics Inc (KYTX) Shareholder Structure: Major Shareholders & Institutional Holdings

This article provides a detailed breakdown of Kyverna Therapeutics Inc (KYTX) shareholder structure, listing major shareholders and their proportional holdings, as well as the types of shareholders. It also presents institutional shareholding data across several quarters, showing

Tone
Neutral 50/100
Event
Market update
Published
17 Jun 2026 08:40
Source
TradingKey
TradingKey Direct company coverage

Kyverna Therapeutics Inc (KYTX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article from TradingKey provides a revenue breakdown for Kyverna Therapeutics Inc (KYTX). It notes that relevant data for business segments, regional revenue, and profit contribution for FY2023, FY2022, and FY2021 have not yet been disclosed by the company. The current stock

Tone
Neutral 50/100
Event
Earnings
Published
17 Jun 2026 07:39
Source
TradingKey
GuruFocus Direct company coverage

Kyverna Therapeutics to Participate in Upcoming September Invest

Kyverna Therapeutics, a clinical-stage biopharmaceutical company focused on autoimmune diseases, announced its participation in three upcoming September investor conferences: the Morgan Stanley Global Healthcare Conference, the Wells Fargo Healthcare Conference, and the Cantor Gl

Tone
Neutral 50/100
Event
Market update
Published
11 Jun 2026 19:09
Source
GuruFocus
Stocktwits Direct company coverage

KYTX Stock Soars After Hours: What’s Driving The Rally?

Kyverna Therapeutics (KYTX) stock surged 24% after hours following the release of strong pivotal trial results for its one-time CAR-T therapy, miv-cel, in patients with stiff person syndrome. The trial showed significant improvements in mobility and disability reversal, with 81%

Tone
Positive 92/100
Event
Earnings
Published
09 Jun 2026 11:10
Source
Stocktwits